Comparing Venclexta vs Venetoclax
| Venclexta (venetoclax) | Venetoclax |
|
|---|
| Venclexta (venetoclax) | Venetoclax |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Venclexta is a BCL-2 inhibitor that may be used to treat chronic lymphocytic leukemia (CLL), small cell lymphoma (SCL), or acute myeloid leukemia. It is an oral tablet that is administered once... View more |
Prescription only
Prescribed for Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia. Venetoclax may also be used for purposes not listed in this medication guide. |
Related suggestions Acute Myeloid Leukemia
Popular comparisons
|
|||||||
| More about Venclexta (venetoclax) | More about Venetoclax | ||||||||
| Ratings & Reviews | |||||||||
|
Venclexta has an average rating of 8.6 out of 10 from a total of 11 ratings on Drugs.com. 82% of reviewers reported a positive effect, while 0% reported a negative effect. |
Venetoclax has an average rating of 9.0 out of 10 from a total of 23 ratings on Drugs.com. 91% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Venclexta side effects |
View all Venetoclax side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Venclexta prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Venclexta | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
26 hours |
26 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 462 drugs are known to interact with Venclexta:
|
A total of 462 drugs are known to interact with Venetoclax:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
April 11, 2016 |
N/A |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Kesimpta
Kesimpta is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated ...
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Brukinsa
Brukinsa is used to treat adults with mantle cell lymphoma, Waldenström’s macroglobulinemia, ma ...
Calquence
Calquence (acalabrutinib) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Zanubrutinib
Zanubrutinib is a targeted treatment that may be used to treat adults with chronic lymphocytic ...
Acalabrutinib
Acalabrutinib (Calquence) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Ibrutinib
Ibrutinib (Imbruvica) is a Bruton's tyrosine kinase inhibitor used for certain blood cancers and ...
Cyclophosphamide
Cyclophosphamide is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, brain ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.